Semaglutide, Tirzepatide
& Retatrutide:
The Complete Deep Dive

This is the deep dive — for people who want more than a surface-level overview. The goal here is to explain the biology: how each of these compounds works at the receptor level, why those differences in mechanism translate into different clinical outcomes, and what that means for anyone using or considering these medications. This is not a prescribing guide. It is an education in the science behind one of the most significant pharmacological developments in metabolic medicine in decades.

The GLP-1 Hormone System

Before examining each medication, understanding the hormone they are designed to amplify is essential. GLP-1 — glucagon-like peptide-1 — is produced naturally in the intestinal L-cells following food intake. Its effects are coordinated across multiple systems: it stimulates glucose-dependent insulin secretion from the pancreas, suppresses glucagon release that would otherwise raise blood sugar, slows gastric emptying to blunt post-meal glucose spikes, and communicates satiety signals directly to the hypothalamus.

In a healthy person, GLP-1 is released after meals and degraded within minutes by the enzyme DPP-4. GLP-1 receptor agonist medications are engineered to activate the same receptor pathways while resisting that enzymatic breakdown — producing sustained effects that the body's own hormone cannot achieve on its own.

Semaglutide — The Established Standard

How It Works

Semaglutide is a selective GLP-1 receptor agonist. Its molecular structure was specifically engineered to mimic GLP-1 while resisting the enzymatic breakdown that degrades the body's natural hormone within minutes. The result is a compound with a half-life measured in days rather than seconds — producing sustained receptor activation across the GLP-1 pathway that the body cannot replicate on its own.

At the biological level, that sustained activation does several things simultaneously. It keeps appetite suppression signals active between meals by engaging GLP-1 receptors in the hypothalamus — the brain region most responsible for hunger regulation. It slows gastric emptying, which extends the physical sensation of fullness after eating. And it modulates insulin and glucagon in a glucose-dependent way, improving blood sugar control without triggering dangerous lows. Semaglutide does not create a new biological process. It amplifies and extends one that already exists in every person.

Clinical Approval & What the Trials Show

Semaglutide is FDA-approved under the brand names Ozempic (type 2 diabetes management) and Wegovy (chronic weight management). The STEP trial program, which forms the clinical foundation for its weight management approval, produced results that meaningfully separated this class of medication from everything that preceded it.

The flagship STEP 1 trial followed adults with obesity over 68 weeks. Participants on semaglutide lost an average of nearly 15% of body weight — compared to 2.4% on placebo. More than 86% achieved at least 5% weight loss, and nearly 70% achieved 10% or more. STEP 3, which paired semaglutide with intensive behavioral intervention, pushed average outcomes to 16% — a clear signal that the medication and structured lifestyle support amplify each other. STEP 4, the discontinuation study, is equally important: participants who stopped semaglutide regained roughly two-thirds of their lost weight within a year, underscoring that the medication manages conditions rather than resolving the underlying patterns that drive them.

The SELECT cardiovascular trial added a significant dimension: semaglutide reduced major adverse cardiovascular events by 20% in adults with established cardiovascular disease and obesity. That result extended the compound's clinical relevance well beyond weight management into long-term cardiometabolic risk reduction.

Tolerability

The most common side effects are gastrointestinal — nausea primarily, along with varying degrees of vomiting, diarrhea, and constipation. These effects are most pronounced early in treatment and are the reason these medications are introduced gradually. For most people, they diminish significantly over time. There are contraindications that any prescribing conversation should address — including personal or family history of medullary thyroid carcinoma or a related condition called Multiple Endocrine Neoplasia syndrome type 2.

Tirzepatide — The Dual Agonist

Why Two Receptors Change the Outcome

Tirzepatide is a dual GLP-1/GIP receptor agonist — meaning it activates two distinct incretin hormone receptor systems simultaneously through a single engineered molecule. GIP, or glucose-dependent insulinotropic polypeptide, is the second major incretin hormone alongside GLP-1. Under healthy metabolic conditions, both are released after eating and work in concert to coordinate insulin secretion and blood sugar regulation.

In people with obesity and insulin resistance, GIP receptor sensitivity is often significantly impaired — the body's responsiveness to this hormone degrades as metabolic dysfunction deepens. Tirzepatide's sustained GIP receptor activation appears to restore that sensitivity over time. The practical result of engaging both systems simultaneously is a broader hormonal response than GLP-1 agonism alone can produce: enhanced fat metabolism, reduced adipose tissue inflammation, and additive insulin secretion that compounds the effects of GLP-1 pathway activation. This is not a minor biological distinction — it is the mechanism behind why tirzepatide's clinical outcomes trend consistently higher than semaglutide's across comparable trial populations.

Clinical Approval & What the Trials Show

Tirzepatide is FDA-approved under the brand names Mounjaro (type 2 diabetes) and Zepbound (weight management). The SURMOUNT trial program established its clinical profile for weight management and produced the highest average weight loss outcomes ever recorded in a pharmaceutical weight loss trial at the time of publication.

SURMOUNT-1, a 72-week study in adults with obesity, showed average weight loss of approximately 21% at the highest studied dose — compared to 3% on placebo. More than half of participants at that dose achieved at least 20% body weight reduction. In the type 2 diabetes population studied in SURMOUNT-2, average outcomes were somewhat lower but still meaningfully higher than what was demonstrated with semaglutide in comparable populations. Individual response varies substantially — these are averages drawn from large trial populations, not predictions for any specific person.

Tolerability

The side effect profile mirrors semaglutide — nausea is the most commonly reported effect, most pronounced in early treatment, and generally diminishing with time. The same contraindications apply. The key clinical takeaway is that greater biological potency through dual-receptor activation does not translate into meaningfully greater tolerability burden.

Retatrutide — The Triple Agonist (Investigational)

What Adding Glucagon Changes

Retatrutide is a triple GLP-1/GIP/glucagon receptor agonist — the third receptor target being glucagon is what separates it biologically from both semaglutide and tirzepatide. Glucagon is most commonly understood as the hormone that raises blood sugar — the counter-regulatory signal to insulin. But glucagon receptor activation in the liver and adipose tissue also plays a direct role in promoting fatty acid oxidation and thermogenesis: the body's production of heat and expenditure of energy.

By engaging all three receptor systems simultaneously, retatrutide is theoretically targeting every major hormonal lever in the incretin and energy expenditure system at once. GLP-1 activity drives appetite suppression and insulin modulation. GIP activity enhances fat metabolism and adds insulin secretion. Glucagon activity increases energy expenditure directly — a pathway neither semaglutide nor tirzepatide activates. The challenge with glucagon receptor agonism is that it would normally raise blood sugar — which is why the engineering of this molecule requires the GLP-1 component to counterbalance that effect. In the Phase 2 trial data, it appears to do so successfully.

What the Early Data Shows

A Phase 2 trial published in the New England Journal of Medicine in 2023 studied retatrutide in adults with obesity over 48 weeks. Average weight loss at the highest studied dose approached 24% — the highest average ever recorded in a pharmaceutical weight loss trial at that time. The proportion of participants achieving meaningful thresholds was similarly striking: every participant at the highest dose achieved at least 5% weight loss, and more than 80% achieved 15% or more.

These numbers must be understood in context. Phase 2 trials are smaller, shorter, and not designed to meet the full evidentiary standard required for FDA approval. Phase 3 trials are ongoing. The data is compelling and explains the significant scientific interest in this compound — but retatrutide is investigational, and the clinical picture will not be complete until larger trial results are available.

Side-by-Side Comparison

Why Body Composition Outcomes Depend on More Than the Medication

Here is something the headlines rarely explain: the number on the scale after GLP-1 treatment is not the same thing as body composition. All three of these compounds work by dramatically reducing appetite — which typically drops total food intake to a level the body has not sustained in years. That caloric deficit drives fat loss. But in a significant deficit, the body does not selectively burn fat. It draws from available tissue, and that includes muscle.

The STEP trial data is instructive here. In participants who were not actively prioritizing protein intake and resistance training, approximately 25–40% of total weight lost was lean mass. For someone who loses 30 pounds, that could mean 8–12 pounds of muscle gone alongside the fat — with lasting consequences for metabolic rate, physical capacity, and the way the body looks and functions when treatment ends. This is not a flaw in the medication. It is what happens when aggressive caloric restriction occurs without the behaviors that protect lean tissue. The medication creates the deficit. What you do inside that deficit determines the quality of the outcome.

Protein intake is the most critical nutritional variable during this process. Appetite suppression powerful enough to drop caloric intake by 30–50% will eliminate hunger as a reliable guide to eating. People naturally gravitate toward smaller, simpler meals — often carbohydrate-based — because they are easier to prepare and require less effort when appetite is low. Protein gets deprioritized by default. The solution is to treat it as a deliberate daily target rather than something that happens naturally. That means hitting an adequate protein intake at every meal, even when eating feels unnecessary. The lean mass preserved during this phase determines what the body looks like and how it functions when the weight loss phase ends.

Resistance training works through a parallel mechanism. Muscle tissue is preserved when the body receives a consistent signal that it is needed. Progressive resistance training provides that signal — it tells the body that the muscle you are carrying is functional and worth maintaining. Remove that signal during a significant caloric deficit and the body has no biological reason to prioritize lean mass preservation. These two behaviors — adequate protein and consistent resistance training — are the difference between losing weight and losing fat. Both matter, and neither can be substituted by the medication.

Key Takeaways

• Semaglutide and tirzepatide are FDA-approved with robust multi-year clinical data. Retatrutide is investigational — not approved, not yet available as a standard treatment.
• Tirzepatide produces higher average weight loss than semaglutide because its dual GLP-1/GIP mechanism engages a broader hormonal response. Individual results vary substantially for both.
• Retatrutide adds glucagon receptor activation — a third distinct biological pathway that may further increase energy expenditure. Early data is compelling, but Phase 3 trials are ongoing.
• Lean mass loss during treatment is common but preventable. Adequate protein intake and consistent resistance training are the primary tools — and they are within your control regardless of which compound is prescribed.
• Discontinuation without a lifestyle foundation leads to predictable regain. The medication manages physiological conditions — it does not resolve the underlying patterns that drive them.
• These medications work best as structure within an intentional approach. The biology creates the conditions. What you build during treatment determines whether the result is lasting.

The Bottom Line

The science on GLP-1 medications is genuinely compelling. Semaglutide and tirzepatide have produced outcomes that were not achievable with previous pharmacological tools for weight management. Retatrutide may eventually extend that ceiling further. What the research also makes clear — consistently, across every major trial — is that outcomes are better, more durable, and more meaningful when the medication is paired with deliberate nutrition, adequate protein, and resistance training. The medication creates conditions. What you build inside those conditions determines whether the result lasts.